Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice

Leukemia

Volumn 29, Issue 2, 2015, Pages 406-414

  Macor, P ^a   Secco, E ^a   Mezzaroba, N ^a   Zorzet, S ^a   Durigutto, P ^a   Gaiotto, T ^b   De Maso, L ^a   Biffi, S ^c   Garrovo, C ^c   Capolla, S ^a   Tripodo, C ^d   Gattei, V ^e   Marzari, R ^a   Tedesco, F ^f   Sblattero, D ^g  

^a UNIVERSITY OF TRIESTE   (Italy)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MB20 55; MONOCLONAL ANTIBODY MB20 59; UNCLASSIFIED DRUG; ANTIBODY; BISPECIFIC ANTIBODY; CD20 ANTIGEN; COMPLEMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL SEPARATION; CHEMISTRY; CYTOLOGY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR CLONING; PROCEDURES; SCID MOUSE;

ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD55; ANTIGENS, CD59; BURKITT LYMPHOMA; CELL SEPARATION; CLONING, MOLECULAR; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE;

EID: 84927171007     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.185     Document Type: Article

References (52)

1. Baker M. Upping the ante on antibodies. Nat Biotechnol 2005; 23: 1065-1072.
2. Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. MAbs 2009; 1: 56-66.
3. Ledford H. 'Biosimilar' drugs poised to penetrate market. Nature 2010; 468: 18-19.
4. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157.
5. Hong CW, Zeng Q. Awaiting a new era of cancer immunotherapy. Cancer Res 2012; 72: 3715-3719.
6. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-1043.
7. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471.
8. Hubert P, Amigorena S. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1: 103-105.
9. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24 : 19-28.
10. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317-327.
11. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) 2011; 16: 277-306.
12. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20: 34-50.
13. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729-740.
14. Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett 2007; 111: 6-13.
15. Maher J, Adami AA. Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies? Cancer Res 2013; 73: 5613-5617.
16. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4944.
17. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30: 798-807.
18. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214: 441-453.
19. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22-30.
20. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226-6233.
21. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171.
22. Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160: 3437-3443.
23. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82: 483-493.
24. Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009; 1173: 865-873.
25. Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008; 101: 737-740.
26. Tedesco F, Bulla B, Fischetti F. Terminal complement complex: regulation of formation and pathophysiological function. In: Szebeni J (ed). The Complement System: Novel Rules in Health and Disease. pp 97-127, 2004.
27. Garred P, Hetland G, Mollnes TE, Stoervold G. Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts. Scand J Immunol 1990; 32: 555-560.
28. Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69-76.
29. Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. APMIS 2001; 109: 73-78.
30. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAbmediated cancer immunotherapy. Trends Immunol 2004; 25: 158-164.
31. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109-123.
32. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175-2183.
33. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556-10563.
34. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88: 1002-1012.
35. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
36. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo . J Immunol 2003; 171: 1581-1587.
37. Di Niro R, Ziller F, Florian F, Crovella S, Stebel M, Bestagno M et al. Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol 2007; 7: 46.
38. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584-590.
39. Hanke T, Szawlowski P, Randall RE. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol 1992; 73(Pt 3): 653-660.
40. Boscolo S, Mion F, Licciulli M, Macor P, De Maso L, Brce M et al. Simple scale-up of recombinant antibody production using an UCOE containing vector. N Biotechnol 2012; 29: 477-484.
41. Macor P, Mezzanzanica D, Cossetti C, Alberti P, Figini M, Canevari S et al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 2006; 66: 3876-3883.
42. Mezzaroba N, Zorzet S, Secco E, Biffi S, Tripodo C, Calvaruso M et al. New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/ hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One 2013; 8: e74216.
43. Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, Secco E et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging 2008; 7: 272-282.
44. Biffi S, Dal Monego S, Dullin C, Garrovo C, Bosnjak B, Licha K et al. Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. PLoS One 2013; 8: e57150.
45. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617-621.
46. Reed CD, Rast H, Hu WG, Mah D, Nagata L, Masri SA. Expression of furin-linked Fab fragments against anthrax toxin in a single mammalian expression vector. Protein Expr Purif 2007; 54: 261-266.
47. Funakoshi S, Longo DL, Murphy WJ. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother Emphasis Tumor Immunol 1996; 19: 93-101.
48. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101 : 1045-1052.
49. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-2743.
50. Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012; 189: 2985-2994.
51. Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo . Blood 2002; 99: 185-192.
52. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225-1235.